A detailed history of Wealthcare Advisory Partners LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealthcare Advisory Partners LLC holds 298 shares of REGN stock, worth $225,529. This represents 0.01% of its overall portfolio holdings.

Number of Shares
298
Previous 297 0.34%
Holding current value
$225,529
Previous $312,000 0.32%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$1024.09 - $1201.76 $1,024 - $1,201
1 Added 0.34%
298 $313,000
Q2 2024

Aug 09, 2024

BUY
$883.2 - $1071.19 $2,649 - $3,213
3 Added 1.02%
297 $312,000
Q1 2024

Apr 15, 2024

BUY
$902.69 - $993.35 $33,399 - $36,753
37 Added 14.4%
294 $282,000
Q4 2023

Feb 06, 2024

BUY
$775.18 - $881.7 $199,221 - $226,596
257 New
257 $225,000
Q2 2021

Aug 16, 2021

SELL
$472.8 - $558.54 $43,024 - $50,827
-91 Closed
0 $0
Q1 2021

Apr 30, 2021

BUY
$446.73 - $548.2 $40,652 - $49,886
91 New
91 $43,000
Q3 2019

Oct 17, 2019

SELL
$273.46 - $318.39 $10,938 - $12,735
-40 Closed
0 $0
Q2 2019

Jul 30, 2019

SELL
$299.6 - $414.82 $4,494 - $6,222
-15 Reduced 27.27%
40 $13,000
Q4 2018

Feb 14, 2019

SELL
$335.82 - $403.04 $9,402 - $11,285
-28 Reduced 33.73%
55 $21,000
Q3 2018

Nov 14, 2018

BUY
$351.14 - $408.51 $5,267 - $6,127
15 Added 22.06%
83 $34,000
Q1 2018

May 15, 2018

SELL
$315.82 - $393.78 $315 - $393
-1 Reduced 1.45%
68 $23,000
Q4 2017

Feb 14, 2018

BUY
$358.63 - $469.95 $15,779 - $20,677
44 Added 176.0%
69 $26,000
Q3 2017

Nov 15, 2017

BUY
$431.38 - $504.0 $10,784 - $12,600
25
25 $11,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Wealthcare Advisory Partners LLC Portfolio

Follow Wealthcare Advisory Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealthcare Advisory Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealthcare Advisory Partners LLC with notifications on news.